WASHINGTON — JC Scott has been the top lobbyist for the pharmacy benefit manager industry for just over four months, but he says he’s ready, willing, and able to defend his industry before Congress.

Scott, who was hired in September as president and CEO of the Pharmaceutical Care Management Association, has his work cut out for him. PBMs, which negotiate with drug makers on behalf of health insurers and employers over the price of drugs, have gotten a bad reputation in Washington as middlemen who needlessly drive up drug prices in order to pocket more money for themselves. But Scott is determined to turn that reputation around, and he believes going before Congress is a key step in doing that.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy